

Alberto Martini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7790139/publications.pdf>

Version: 2024-02-01

114
papers

1,790
citations

318942

23
h-index

388640

36
g-index

116
all docs

116
docs citations

116
times ranked

2068
citing authors

#	ARTICLE	IF	CITATIONS
1	Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings. <i>European Urology Oncology</i> , 2022, 5, 187-194.	2.6	20
2	Metastatic hormone-sensitive prostate cancer: local treatment strategies. <i>World Journal of Urology</i> , 2022, 40, 881-882.	1.2	1
3	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 10.e1-10.e6.	0.8	20
4	The obesity paradox in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 472-478.	2.0	15
5	Detection of Prostate Cancer Using Biparametric Prostate MRI, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 465-477.	1.9	9
6	Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. <i>European Urology Focus</i> , 2022, 8, 1270-1277.	1.6	11
7	An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 350-357.	0.2	13
8	The Role of 3D Models Obtained from Multiparametric Prostate MRI in Performing Robotic Prostatectomy. <i>Journal of Endourology</i> , 2022, 36, 387-393.	1.1	5
9	External validation of the Palacios equation: a simple and accurate tool to estimate the new baseline renal function after renal cancer surgery. <i>World Journal of Urology</i> , 2022, 40, 467-473.	1.2	10
10	Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102360.	3.4	22
11	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. <i>World Journal of Urology</i> , 2022, 40, 1167-1174.	1.2	9
12	Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. <i>European Urology Oncology</i> , 2022, 5, 30-41.	2.6	11
13	The Paradoxical Role of Body Mass Index in Patients with Muscle-invasive Bladder Cancer Receiving Neoadjuvant Immunotherapy. <i>European Urology Oncology</i> , 2022, 5, 370-372.	2.6	2
14	Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 389.e1-389.e7.	0.9	1
15	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer: Current State and Future Perspectives. <i>Cancers</i> , 2022, 14, 147.	1.7	2
16	Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring. <i>Cancer</i> , 2022, 128, 2892-2897.	2.0	6
17	Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 451-459.	2.6	11
18	Acute kidney injury and functional outcomes after partial nephrectomy. <i>International Journal of Urology</i> , 2022, 29, 1243-1244.	0.5	1

#	ARTICLE	IF	CITATIONS
19	The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator. <i>European Urology Open Science</i> , 2022, 11, 45-54.	0.2	4
20	Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 384.e15-384.e21.	0.8	3
21	Multidisciplinary team referral at diagnosis for patients with non-metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 384.e9-384.e14.	0.8	2
22	Hood Technique for Robotic Radical Prostatectomyâ€”Preserving Periurethral Anatomical Structures in the Space of Retzius and Sparing the Pouch of Douglas, Enabling Early Return of Continence Without Compromising Surgical Margin Rates. <i>European Urology</i> , 2021, 80, 213-221.	0.9	68
23	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). <i>European Urology Oncology</i> , 2021, 4, 971-979.	2.6	56
24	Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors. <i>European Urology Focus</i> , 2021, 7, 574-581.	1.6	30
25	Can anesthetics affect bladder cancer recurrence? Total intravenous versus volatile anesthesia in patients undergoing robot-assisted radical cystectomy: A single institution retrospective analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 233.e1-233.e8.	0.8	10
26	Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion. <i>International Journal of Urology</i> , 2021, 28, 47-52.	0.5	11
27	Editorial Comment from Dr Martini <i>et Al</i>. to Independent external validation of a nomogram to define risk categories for a significant decline in estimated glomerular filtration rate after roboticâ€”assisted partial nephrectomy. <i>International Journal of Urology</i> , 2021, 28, 80-81.	0.5	0
28	RE: Validating the Martini Staging System for Rectourethral Fistula: A Meta-analysis of Postoperative Outcomes. <i>Urology</i> , 2021, 147, 323.	0.5	0
29	How to Select the Optimal Candidates for Renal Mass Biopsy. <i>European Urology Oncology</i> , 2021, 4, 506-509.	2.6	10
30	Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 42-48.	2.6	40
31	Defining Risk Categories for a Significant Decline in Estimated Glomerular Filtration Rate After Robotic Partial Nephrectomy: Implications for Patient Follow-up. <i>European Urology Oncology</i> , 2021, 4, 498-501.	2.6	11
32	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 301-304.	2.6	2
33	On the use of the â€œPopulation Attributable Fractionâ€” application in cost estimation. <i>Translational Andrology and Urology</i> , 2021, 10, 22-23.	0.6	0
34	Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1369-1376.	1.2	34
35	Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 743-749.	2.0	4
36	Salvage Robot-assisted Renal Surgery for Local Recurrence After Surgical Resection or Renal Mass Ablation: Classification, Techniques, and Clinical Outcomes. <i>European Urology</i> , 2021, 80, 730-737.	0.9	12

#	ARTICLE	IF	CITATIONS
37	Unexpected Outcomes of Renal Function after Radical Nephrectomy: Histology Relevance along with Clinical Aspects. <i>Journal of Clinical Medicine</i> , 2021, 10, 3322.	1.0	5
38	Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. <i>Minerva Urology and Nephrology</i> , 2021, 73, 481-488.	1.3	5
39	Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 885-893.	0.2	11
40	Evidence-based Urology: Surrogate Endpoints “ Pro. <i>European Urology Focus</i> , 2021, 7, 1217-1218.	1.6	3
41	How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database. <i>Acta Radiologica Open</i> , 2021, 10, 205846012110607.	0.3	1
42	Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, , .	0.8	6
43	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	3
44	Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators. <i>European Urology Oncology</i> , 2020, 3, 700-704.	2.6	69
45	Development of a model to predict prostate cancer at the apex (PCAP model) in patients undergoing robot-assisted radical prostatectomy. <i>World Journal of Urology</i> , 2020, 38, 813-819.	1.2	7
46	The natural history of untreated muscle-invasive bladder cancer. <i>BJU International</i> , 2020, 125, 270-275.	1.3	72
47	Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1075-1085.	1.9	24
48	Does race impact functional outcomes in patients undergoing robotic partial nephrectomy?. <i>Translational Andrology and Urology</i> , 2020, 9, 863-869.	0.6	1
49	Weighted Gleason Grade Group (WGGG): A new prostate cancer biopsy reporting system with prognostic potential. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 78.e15-78.e21.	0.8	3
50	A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection. <i>BJU International</i> , 2020, 125, 531-540.	1.3	32
51	Re: Antonio C. Westphalen, Charles E. McCulloch, Jordan M. Anaokar, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. <i>Radiology</i> 2020;296:76-84. <i>European Urology Oncology</i> , 2020, 3, 714-715.	2.6	1
52	Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy. <i>European Urology</i> , 2020, 78, 583-591.	0.9	78
53	Ureteral location is associated with survival outcomes in upper tract urothelial carcinoma: A population-based analysis. <i>International Journal of Urology</i> , 2020, 27, 966-972.	0.5	8
54	Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database. <i>Bladder Cancer</i> , 2020, 6, 265-276.	0.2	5

#	ARTICLE	IF	CITATIONS
55	Quantitative Polymerase Chain Reaction Detection of Microchimerism in Female Transplant Renal Recipients. <i>Urologia Internationalis</i> , 2020, 104, 865-870.	0.6	1
56	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. <i>European Urology Oncology</i> , 2020, 3, 739-747.	2.6	31
57	The effect of tumor location on overall survival for pT2-4 bladder and upper tract urothelial carcinoma following radical surgery. <i>Canadian Urological Association Journal</i> , 2020, 15, E248-E255.	0.3	0
58	Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 638-645.	2.0	9
59	Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy. <i>JAMA Network Open</i> , 2020, 3, e201913.	2.8	15
60	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2020, 78, 138-142.	0.9	55
61	Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 684.e9-684.e15.	0.8	8
62	Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy. <i>Journal of Urology</i> , 2020, 204, 82-90.	0.2	24
63	Performance of prostate multiparametric MRI for prediction of prostate cancer extra-prostatic extension according to NCCN risk categories: implication for surgical planning. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 746-754.	3.9	18
64	Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data.. <i>Journal of Clinical Oncology</i> , 2020, 38, 75-75.	0.8	0
65	Black race may be associated with worse overall survival in renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 938.e9-938.e17.	0.8	6
66	Conditionally Reprogrammed Patient-derived Cells: A Step Forward Towards Personalized Medicine?. <i>European Urology</i> , 2019, 76, 435-436.	0.9	6
67	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 599-603.	0.9	95
68	Novel nomogram for the prediction of seminal vesicle invasion including multiparametric magnetic resonance imaging. <i>International Journal of Urology</i> , 2019, 26, 458-464.	0.5	12
69	Anatomic robotic prostatectomy: current best practice. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721881378.	0.9	13
70	Anatomical, surgical and technical factors influencing continence after radical prostatectomy. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721881378.	0.9	27
71	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. <i>Cancer</i> , 2019, 125, 3155-3163.	2.0	32
72	Re: Jacob A. Burns, Adam B. Weiner, William J. Catalone, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. <i>Eur Urol</i> 2019;75:846-52. <i>European Urology</i> , 2019, 76, e98.	0.9	0

#	ARTICLE	IF	CITATIONS
73	Renal cell carcinoma: the oncological outcome is not the only endpoint. <i>Translational Andrology and Urology</i> , 2019, 8, S93-S95.	0.6	9
74	Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 782-789.	0.9	38
75	Predicting acute kidney injury after robot-assisted partial nephrectomy: Implications for patient selection and postoperative management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 445-451.	0.8	24
76	Image guidance in robot-assisted radical prostatectomy. <i>Current Opinion in Urology</i> , 2019, 29, 10-13.	0.9	5
77	A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome. <i>BJU International</i> , 2019, 124, 155-162.	1.3	7
78	Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. <i>BJU International</i> , 2019, 124, 665-671.	1.3	34
79	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e541-e548.	0.9	6
80	Downgrading of Grade Group After Radical Prostatectomy: Comparison of Multiparametric Magnetic Resonance Imaging Guided Fusion Biopsy and Standard 12-Core Biopsy. <i>Urology</i> , 2019, 127, 80-85.	0.5	12
81	Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 456-463.	2.6	13
82	An updated approach to incremental nerve sparing for robot-assisted radical prostatectomy. <i>BJU International</i> , 2019, 124, 103-108.	1.3	21
83	What is new in robot-assisted radical prostatectomy. <i>Current Opinion in Urology</i> , 2019, 29, 14-18.	0.9	4
84	Sildenafil: An Update on Efficacy, Safety and Clinical Indications in Urology. <i>Advances in Therapy</i> , 2019, 36, 1-18.	1.3	14
85	Hypertension and diabetes mellitus are not associated with worse renal functional outcome after partial nephrectomy in patients with normal baseline kidney function. <i>International Journal of Urology</i> , 2019, 26, 120-125.	0.5	8
86	Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests. <i>Journal of Urology</i> , 2019, 202, 102-107.	0.2	27
87	The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study. <i>Journal of Urology</i> , 2019, 202, 108-113.	0.2	67
88	Risk factors and prognostic implications for pathologic upstaging to T3a after partial nephrectomy. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 395-405.	3.9	15
89	Obesity and metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 287-287.	0.8	0
90	The impact of pathologic downstaging with neoadjuvant chemotherapy on survival of patients with muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 491-491.	0.8	0

#	ARTICLE	IF	CITATIONS
91	The potential role of germline single nucleotide polymorphisms for selecting the ideal candidates for sunitinib therapy in patients with locally-advanced renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S37-S37.	0.7	0
92	Clinical implications of prostatic capsular abutment or bulging on multiparametric magnetic resonance imaging. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 502-507.	3.9	6
93	Development and internal validation of a side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer. <i>BJU International</i> , 2018, 122, 1025-1033.	1.3	86
94	Re: Serra-Aracil et al.: The Place of Transanal Endoscopic Surgery in the Treatment of Rectourethral Fistula (<i>Urology</i> 2018;111:139-144). <i>Urology</i> , 2018, 115, 193-194.	0.5	2
95	Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 310.e1-310.e6.	0.8	8
96	Long-term experience with a novel uterine-sparing transvaginal mesh procedure for uterovaginal prolapse. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 222, 57-63.	0.5	1
97	Re: Rita Faria, Marta O. Soares, Eldon Spackman, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). <i>Eur Urol</i> 2018;73:23-30. <i>European Urology</i> , 2018, 73, e108-e109.	0.9	5
98	Evaluating the role of neoadjuvant chemotherapy in bladder cancer patients with occult lymph node metastases. <i>Translational Andrology and Urology</i> , 2018, 7, 742-744.	0.6	3
99	The role of antibiotic prophylaxis after radical cystectomy in preventing urinary tract infections and readmission for sepsis. <i>Translational Andrology and Urology</i> , 2018, 7, 752-753.	0.6	0
100	A Novel Classification Proposal for Rectourethral Fistulas After Primary Treatment of Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 510-511.	2.6	11
101	Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level. <i>Journal of Urology</i> , 2018, 200, 1241-1249.	0.2	23
102	A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial Nephrectomy. <i>European Urology</i> , 2018, 74, 833-839.	0.9	76
103	Minimally Invasive Transanal Repair of Rectourethral Fistulas. <i>European Urology</i> , 2017, 71, 133-138.	0.9	19
104	Editorial comment to: Ileal versus sigmoid neobladder as bladder substitute after radical cystectomy for bladder cancer: A meta-analysis. <i>International Journal of Surgery</i> , 2017, 37, 13-14.	1.1	2
105	Long-term complications arising from bowel interposition in the urinary tract. <i>International Journal of Surgery</i> , 2017, 44, 278-280.	1.1	17
106	Prostatic Abscess in a Patient with Chronic Granulomatous Disease: A Multi-Disciplinary Intervention. <i>Urologia</i> , 2017, 84, 267-269.	0.3	3
107	Bladder Cancer to Patients Younger than 30 Years: A Retrospective Study and Review of the Literature. <i>Urologia</i> , 2017, 84, 231-235.	0.3	7
108	Conservative Approach for a Solitary Fibrous Tumor of the Kidney. <i>Urologia</i> , 2016, 83, 221-223.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Use of sigmoid colon in orthotopic neobladder reconstruction: Long-term results. International Journal of Urology, 2016, 23, 984-990.	0.5	9
110	Robotic vesico-vaginal fistula repair with no omental flap interposition. International Urogynecology Journal, 2016, 27, 1277-1278.	0.7	10
111	Conservative Treatment of Serous Borderline Paratesticular Tumor in a Pediatric Patient. Urology, 2016, 89, 123-125.	0.5	6
112	Response to Editorial Comment to Use of sigmoid colon in orthotopic neobladder reconstruction: Long-term results. International Journal of Urology, 2016, 23, 991-991.	0.5	2
113	Antihistone antibodies in antinuclear antibody-positive juvenile Arthritis. Arthritis and Rheumatism, 1990, 33, 1836-1841.	6.7	37
114	Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma. Current Opinion in Urology, 0, Publish Ahead of Print, .	0.9	1